Clearmind Medicine Inc. has received an invitation to participate in the Frontiers of Mental Health and Recovery Summit in Washington D.C., a significant event that underscores the increasing interest in psychedelic therapies for mental health treatment. This invitation comes as the company continues to develop non-hallucinogenic psychedelic-derived neuroplastogens aimed at treating various disorders, including Alcohol Use Disorder (AUD).

The summit, convened by BrainFutures with support from the Steven & Alexandra Cohen Foundation, aims to bring together a select group of leaders in mental health care to discuss how to accelerate the readiness of systems for psychedelic therapies. Clearmind's Chief of Global Impact, Mary-Elizabeth Gifford, will represent the company at this event, which is expected to foster collaboration among researchers, clinicians, and policymakers.

Background

Clearmind Medicine Inc., incorporated in Vancouver, British Columbia, operates within the pharmaceutical preparations sector (SIC 2834). The company is publicly traded on the Nasdaq under the ticker CMND. Clearmind focuses on the discovery and development of non-hallucinogenic, second-generation neuroplastogen-derived therapeutics to address prevalent health issues, particularly AUD.

What the Filing Says

According to the recent filing dated November 10, 2026, Clearmind announced its invitation to the summit, stating, "Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit." The event aims to tackle the challenges of integrating psychedelic therapies into mainstream mental health care.

Impact

This invitation may positively impact Clearmind's reputation and visibility within the biopharmaceutical industry, particularly as it relates to the emerging field of psychedelic medicine. The participation of key figures from the FDA and other health organizations at the summit could also influence regulatory perspectives on psychedelic therapies.

What's Next

The filing does not say what happens next.